1Langahl BL,Carstens M,Stenkjaer L,et al.Polymorphisms in the Osteoprote-gerin gene areassociated with osteoporotic fractures.J Bone Miner Res,2002,17 Suppl 7:1245-1255.
2Yasuda H,Shima N,Nakagawa N,et al.Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinilogy,1998,139:1329-1337.
3Arko B,Prezelj J,Komel R,et al.Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.J Clin Endocrinol Metab,2002,87:4080-4084.
4Brandstrom H,Gerdhem P,Stiger F,et al.Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women.Calcif Tissue Int,2004,74:18-24.
2Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res,2000, 15:993-1000.
3Deeb SS, Fajas L, Nemoto M, et al. A Prol2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998, 20:284-287.
4Ogawa S, Urano T, Hosoi T, et al. Association of bone minera density with a polymorphism of the peroxisome proliferator activated receptor γ gene: PPARγ expression in osteoblasts. Biochemical and Biophysical Research Communication, 1999, 260: 122-126.
5Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-gamma2 pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes, 2001, 50:886-890.
6Orio F Jr, Matarese G, Di Biase S, et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab, 2003,88:5887-5892.
7Rhee EJ, Oh KW, Lee WY, et al, The effects of C161->T polymorphisms in exon 6 of peroxisome proliferator activated receptor gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle aged women. Am J Obstet Gynecol, 2005, 192:1087-1093.
8Wang XL, Oosterhof J, Duarle N. Peroxisome proliferator-activated receptor gamma C161->T polymorphism and coronary artery disease. Cardiovase Res, 1999, 44:588-594.
9Nuttall ME, Gimble JM. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone, 2000, 27:177-184.
10Shi XM, Blair HC, Yang X, et al. Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipoeyte differentiation, J Cell Biochem, 2000, 76:518-527.
